Vanda Pharmaceuticals Inc. (VNDA) has released an update.
Vanda Pharmaceuticals Inc. has recently rewarded its executive officers with substantial bonuses for their 2023 performance, with the CEO receiving nearly $1 million. The company’s Compensation Committee also set the 2024 base salaries and target bonuses for these top executives, alongside granting restricted stock units that will vest over four years starting from March 2025. The financial rewards reflect the company’s commitment to aligning executive incentives with its growth and success, a move likely to capture the interest of investors monitoring executive compensation trends.
For further insights into VNDA stock, check out TipRanks’ Stock Analysis page.
